Quote:

---

Good Afternoon,

It's simple, there are two distinct groups that have single-handedly killed the pps and will continue to do so as long as they are in. (really sad to see). One group was not hurting the stock originally, but after the second came in and took minimal profits and sold at every turn without remorse, the first group started selling to try to protect their investment. If you follow the 8k's you know who they are. They are not looking for high multiples, only making a good profit on the conversions and moving on.

As we speak, Gerald (who honestly works harder than anyone in here understands or gives him credit for) is overseas in talks with a potential partner to do a huge convertible note buy back and take back control from these two groups and shrink the possible share increase dramatically. Also, it will include working capital for the ESS and Eltoprazine studies. Once the two groups are out of the picture, the stock will within a week go up in my estimation 15-20X. Putting the market cap back in the range it should be based on the independent evaluations of there current IP portfolio ($100-140M). (no multiplier, minus debt). Then with positive results, we can head towards the (in my opinion, a bit high) price target of $45.35 laid out by independent equity research firm Seethruequity today.

You all know the IP that Amarantus holds, there over 200 patent portfolio...and there many applications. What do you think their market cap should be? At the time I'm writing this it is at $5.5M. Gerald was offered $5M for Eltoprazine alone before the last positive study, and at that time he said nicely...no thank you.

Do your due diligence and know what you own.

Doc

---